Institute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, 18057 Rostock, Germany.
Cells. 2020 Jul 24;9(8):1771. doi: 10.3390/cells9081771.
The modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes in lymph nodes. Different sphingosine 1-phosphate receptor subtypes are expressed in the brain and spinal cord, and their pharmacological effects may improve disease development and neuropathology. Siponimod (BAF312) is a novel sphingosine 1-phosphate receptor modulator that has recently been approved for the treatment of active secondary progressive multiple sclerosis (MS). In this review article, we summarize recent evidence suggesting that the active role of siponimod in patients with progressive MS may be due to direct interaction with central nervous system cells. Additionally, we tried to summarize our current understanding of the function of siponimod and discuss the effects observed in the case of MS.
鞘氨醇 1-磷酸受体的调节是复发性多发性硬化症的一种已批准的治疗方法，因为它具有抗炎作用，可以将淋巴细胞保留在淋巴结中。不同的鞘氨醇 1-磷酸受体亚型在大脑和脊髓中表达，其药理作用可能改善疾病的发展和神经病理学。西尼莫德（BAF312）是一种新型的鞘氨醇 1-磷酸受体调节剂，最近已被批准用于治疗活跃的继发进展性多发性硬化症（MS）。在这篇综述文章中，我们总结了最近的证据，表明西尼莫德在进展性 MS 患者中的积极作用可能是由于其与中枢神经系统细胞的直接相互作用。此外，我们还试图总结我们对西尼莫德功能的现有认识，并讨论在 MS 病例中观察到的影响。
